*Estimate is based on IQVIA US sales and prescription data from April 2017 to May 2019.
(95% CI: 23.3, 43.8) (n=29/88)
of patients had received ≥2 lines of previous therapy
*Response criteria were defined according to RECIST v1.1.
Additional response data3
*These data on durations of response are based on different data with a minimum of 2 years of follow-up in all patients (EMR 100070-003) Part A; cutoff date September 26, 2017). The relative frequencies presented do not account for censoring.
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Merkel Cell Carcinoma V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed May 20, 2021. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way. 2. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-1385. 3. Data on file. Rockland, Mass: EMD Serono, Inc.